Duodenal Obstruction as First Presentation of Metastatic Breast Cancer by Sami Khairy, Ayman Azzam, Shamayel Mohammed, Kausar Suleman, Abdurahman Khawaji, Tarek Amin

“…The metastatic breast cancer to the duodenum is rare in spite of common breast cancer. …”
Get full text

Pretreatment Thrombocytosis as a Prognostic Factor in Metastatic Breast Cancer by Athina Stravodimou, Ioannis A. Voutsadakis

“…We sought to determine if thrombocytosis is also a prognostic factor in metastatic breast cancer. Patients and Methods. The records of 165 metastatic breast cancer patients with complete follow-up that had thrombocytosis or normal platelet counts were reviewed. …”
Get full text

Stroke associated with microvascular tumoral infiltration in a patient with metastatic breast cancer by Joshua Mangerel, MD, Andres Rodriguez-Sein, MD, Daniel Masri, MD

Subjects: Get full text

Gliadin encapsulated PCOs nanoformulation: An effective therapeutic option for metastatic breast cancer by Sant Lal, Monika Kataria, Neeraj Dilbaghi

Subjects: Get full text

Atezolizumab-Induced Sarcoidosis-Like Reaction in a Patient with Metastatic Breast Cancer by Akira Tsunoda, Toshiro Mizuno, Shohei Iida, Katsunori Uchida, Masako Yamashita, Koshi Sukeno, Hiroki Oka, Yasutaka Tono, Mikiya Ishihara, Kanako Saito, Satoshi Tamaru, Keiichi Yamanaka, Isao Tawara

Get full text

Evaluating risk factors for Trastuzumab-Deruxtecan Pneumonitis in patients with metastatic breast cancer by Jonathan Henricks, Tyler Haddad, Omair Ahmed, Jonathan Schoenhals, Pavnesh Kumar, Ryan Wilson, Jianing Ma, Jing Gennie Wang, Michael Wert, Vincent Esguerra, Ian Bentley, Kai Johnson, Daniel Stover, Sachin R. Jhawar, Margaret Gatti-Mays, Kevin Ho

“…Abstract Background Trastuzumab deruxtecan (T-DXd) is FDA-approved for treatment of patients with HER2 positive and HER2-low metastatic breast cancer. Currently, there is limited understanding of pre-treatment risk factors for pneumonitis associated with T-DXd. …”
Get full text

Metastatic Breast Cancer to the Gastrointestinal Tract: Report of Five Cases and Review of the Literature by Massimo Ambroggi, Elisa Maria Stroppa, Patrizia Mordenti, Claudia Biasini, Adriano Zangrandi, Emanuele Michieletti, Elena Belloni, Luigi Cavanna

Get full text

Adipocyte heterogeneity and tumor infiltration of adipose tissue in patients with metastatic breast cancer by Hava Izci, Gitte Zels, Anirudh Pabba, Marion Maetens, François Richard, Maxim De Schepper, Josephine Van Cauwenberge, Ha-Linh Nguyen, Kristien Borremans, Sophia Leduc, Karen Van Baelen, Sigrid Hatse, Tatjana Geukens, Amena Mahdami, Hans Wildiers, Patrick Neven, Wouter Van Den Bogaert, Giuseppe Floris, Christine Desmedt

“…Our understanding of the adipocytes which compose the adipose tissue in different anatomical locations of the body as well as potential microscopic tumor infiltration in patients with metastatic breast cancer remains limited. This study therefore investigates regional variations in adipocyte size and adipose tissue tumor infiltration in patients with metastatic breast cancer. …”
Get full text

The Evolution of Radiation Therapy in Metastatic Breast Cancer: From Local Therapy to Systemic Agent by Jessica M. S. Jutzy, Jeffrey M. Lemons, Jason J. Luke, Steven J. Chmura

“…Radiation therapy is a mainstay of treatment in early and locally advanced breast cancer but is typically reserved for palliation of symptomatic lesions in patients with metastatic breast cancer. With new advances in the field of tumor biology and immunology, the role of radiation in the metastatic setting is evolving to harness its immune-enhancing properties. …”
Get full text

Evaluating the impact of a tertiary multidisciplinary meeting in metastatic breast cancer: A prospective study by Belinda Sassé, Sammy Shaya, Jessica Nimmo, Katie Cao, Daphne Day, Katie Evans, Catherine Healy, Gwo-Yaw Ho, Gillian Kruss, Amelia McCartney, Linda Mojzisova, Ranjana Srivastava, Jennifer Tan, Mun Yee Tan, Kate Webber, Michelle White, Steven David, Marion Harris

“…Background: Metastatic breast cancer (mBC) guidelines recommend multidisciplinary meetings (MDM), but there is limited research on their impact. …”
Get full text

CARDIAC-STAR: prevalence of cardiovascular comorbidities in patients with HR + /HER2 − metastatic breast cancer by Susan Dent, Avirup Guha, Heather Moore, Doris Makari, Rachael McCaleb, Irene Arias, Stella Stergiopoulos, Benjamin Li, Michael Fradley

Subjects: Get full text

Metastatic Breast Cancer Presenting as Fulminant Hepatic Failure: A Case Report and Literature Review by Malcolm S. Trimble, Cameron N. Ghent, David R. Grant, Caroline A. McLean

Get full text

Motivations and perceptions for physical activity in women living with metastatic breast cancer: a qualitative interview study by Mark Liu, Sharon Kilbreath, Jasmine Yee, Jane Beith, Justin McNab, Elizabeth Dylke

“…Methods Women living with metastatic breast cancer were recruited through a metropolitan cancer centre in Australia to participate in semi-structured interviews about their physical activity. …”
Get full text

Medication patterns and potentially inappropriate medication in patients with metastatic breast cancer: results of the BRE-BY-MED study by Lilly Sophia Brandstetter, Anna Grau, Peter U. Heuschmann, Max Müller-Reiter, Jessica Salmen, Stefan Störk, Achim Wöckel, Jens-Peter Reese

Subjects: “…Metastatic breast cancer…”
Get full text

Impacts of genomic alterations on the efficacy of HER2-targeted antibody–drug conjugates in patients with metastatic breast cancer by Riqing Huang, Anqi Hu, Qixiang Rong, Ditian Shu, Meiting Chen, Wei Yang, Yue Zhang, Qiufan Zheng, Xin An, Cong Xue, Haifeng Li, Yanxia Shi

“…Hence, this study aims to identify factors predicting sensitivity to HER2 ADC in metastatic breast cancer. Methods This comprehensive real-world retrospective study collected clinical data from patients diagnosed with metastatic breast cancer and performed genomic profiling using targeted next-generation sequencing. …”
Get full text

Advancing treatment choices: CDK4/6 inhibitor switching in HR+/HER2- metastatic breast cancer by Paola Zagami, Angela Esposito, Beatrice Taurelli Salimbeni, Pier Paolo Maria Berton Giachetti, Roberta Scafetta, Matteo Lambertini, Massimo Di Maio, Giuseppe Curigliano, Carmen Criscitiello, Saverio Cinieri

“…Purpose: CDK4/6 inhibitors (CDK4/6i) use has revolutionized the treatment of hormone receptor-positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) metastatic breast cancer. The choice of a specific CDK4/6i may be influenced by adverse events (AEs). …”
Get full text

Metronomic Cyclophosphamide and Methotrexate Chemotherapy Combined with 1E10 Anti-Idiotype Vaccine in Metastatic Breast Cancer by Jorge L. Soriano, Noyde Batista, Eduardo Santiesteban, Mayté Lima, Joaquín González, Robin García, Yohanka Zarza, María V. López, Myriam Rodríguez, Jorge L. Loys, Narciso Montejo, Frank Aguirre, Amparo Macías, Ana M. Vázquez

“…The use of low doses of cytotoxic agents continuously for prolonged periods is an alternative for the treatment of patients with metastatic breast cancer who have developed resistance to conventional chemotherapy. …”
Get full text

Trifluridine-tipiracil in previously treated patients with oestrogen receptor-positive, HER2-negative metastatic breast cancer (BOOG 2019-01 TIBET trial): a single-arm, multicentre, phase 2 trialResearch in context by Niels A.D. Guchelaar, Ron H.J. Mathijssen, Maaike de Boer, Marlies L. van Bekkum, Joan B. Heijns, Birgit E.P.J. Vriens, Mandy M. van Rosmalen, Lonneke W. Kessels, Lisanne Hamming, Karin J. Beelen, Peter Nieboer, Susan M. van den Berg, Esther Oomen-de Hoop, Rhodé M. Bijlsma, Monique E.M.M. Bos

Subjects: Get full text

Lipid‐coated bismuth nanoflower as the thermos‐radio sensiti for therapy of lung metastatic breast cancer: Preparation, optimisation, and characterisation by Shushu Xue, Junrong Jiao, Si Miao, Lijun Wang, Yang Liu, Qingjie Zhang, Qiyue Wang, Yu Xi, Yuanyuan Zhang

Subjects: Get full text

Cost Effectiveness Analysis of Eribulin Mesylate as a Treatment for Metastatic Breast Cancer in Spain: Management in the Later Line of Therapy by Gabriel Tremblay, Unnati Majethia, Ilias Kontoudis, Jesús De Rosendo

“…**Background:** Two thirds (62%) of metastatic breast cancer (MBC) patients in Western Europe have human epidermal growth factor receptor 2 (HER2)-negative disease, for which anthracyclines and taxanes are recommended as first-line treatments, followed by microtubule-targeting agents such as capecitabine, vinorelbine and/or eribulin. …”
Get full text